Lupin (NSE: LUPIN) secures CGT exclusivity for Risperidone LAI, launches first PrecisionSphere injectable in U.S.

Lupin Limited (NSE: LUPIN), a global pharmaceutical leader headquartered in Mumbai, has officially launched its first long-acting injectable in the United States with the release of Risperidone extended-release injectable suspension. The new product is available in three strengths, 25 mg, 37.5 mg, and 50 mg single-dose vials, and has been granted 180-day Competitive Generic Therapy (CGT) exclusivity by the United States Food and Drug Administration. This exclusive marketing window represents a critical commercial and strategic breakthrough for Lupin Limited, as it becomes the first Indian pharmaceutical company to bring a proprietary long-acting injectable formulation to the U.S. market using in-house technology.

Why does Lupin’s CGT exclusivity for Risperidone mark a strategic inflection point in U.S. generics?

The launch marks the commercial debut of Lupin Limited’s PrecisionSphere microsphere platform, developed by its Dutch subsidiary Nanomi B.V. The injectable product is bioequivalent and therapeutically equivalent to Johnson & Johnson’s Risperdal Consta, an established treatment for schizophrenia and bipolar I disorder. According to IQVIA data for the 12-month period ending September 2025, the reference listed drug generated approximately USD 187 million in combined U.S. sales across all strengths. With CGT exclusivity secured, Lupin Limited has an exclusive opportunity to capture a sizable share of this market without immediate competition from other generics, making the launch financially significant and strategically aligned with its complex generics roadmap.

How does the PrecisionSphere platform solve critical challenges in long-acting injectable delivery?

PrecisionSphere is a proprietary microsphere-based drug delivery system engineered to enable extended-release injectables with consistent dosing profiles. It offers several differentiating advantages, including uniform microsphere size, improved injectability through smaller-gauge needles, and reliable drug concentrations over periods ranging from weeks to months. These features address critical challenges in the long-acting injectable space, particularly in psychiatry and chronic care therapy areas, where adherence and stable plasma levels are key clinical concerns.

How is Lupin shifting its U.S. strategy from high-volume generics to complex, differentiated platforms?

The U.S. launch of Risperidone signals a shift in Lupin Limited’s generics strategy. The company is no longer solely focused on first-to-file or high-volume generics. Instead, it is targeting complex formulations and specialty platforms that offer better margins and longer lifecycle value. In this context, the CGT exclusivity granted by the United States Food and Drug Administration is not just a temporary commercial advantage but also a validation of Lupin Limited’s R&D and regulatory capabilities in high-barrier-to-entry segments.

What does Lupin’s leadership say about the future of the PrecisionSphere platform in global markets?

Spiro Gavaris, President of U.S. Generics at Lupin Limited, described the launch as a key milestone that demonstrates the company’s ability to bring complex injectables to market. He noted that the deployment of PrecisionSphere in a commercially approved product reinforces the platform’s viability and underlines Lupin Limited’s commitment to differentiated drug delivery. The company is now poised to scale the platform for additional products and therapeutic classes.

Dr. Fabrice Egros, President of Corporate Development at Lupin Limited, added that the successful launch positions the company to expand access to advanced long-acting injectable treatments globally. He emphasized that Lupin Limited is actively seeking strategic collaborations with other pharmaceutical companies looking to extend the lifecycle of their products through longer-acting formulations. This dual strategy of building an internal pipeline while offering the platform for external collaborations sets Lupin Limited apart from peers who may be limited to either a proprietary model or a service model.

Why is Nanomi B.V. seen as central to Lupin’s innovation roadmap for microsphere-based delivery?

From a platform development perspective, PrecisionSphere is the culmination of years of research by Nanomi B.V., a company that Lupin Limited acquired to enhance its capabilities in microsphere drug delivery. The Dutch subsidiary has played a critical role in transforming what was once a technical concept into a regulatory-compliant, commercially viable injectable format. With this foundation now validated through regulatory approval and commercial rollout, PrecisionSphere is expected to be central to Lupin Limited’s long-term innovation strategy.

How are global regulatory trends supporting long-acting injectables across chronic disease areas?

The broader long-acting injectable market is gaining strategic relevance among global pharmaceutical firms. Therapies designed for monthly or quarterly dosing can significantly improve patient adherence and reduce healthcare system costs. Regulatory agencies in the United States, European Union, and Asia are also supporting this trend by expediting reviews for long-acting formulations, particularly in psychiatry, endocrinology, and oncology. Lupin Limited’s entry into this segment aligns well with these regulatory tailwinds and evolving patient needs.

What are the approved indications and clinical positioning of Lupin’s Risperidone injectable?

The product itself, Risperidone extended-release injectable suspension, is indicated for the treatment of schizophrenia in adults. It is also approved for use as a monotherapy or in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. These are high-burden psychiatric conditions where consistent medication delivery is crucial for symptom control and relapse prevention. By offering a more convenient and predictable formulation, Lupin Limited aims to improve outcomes for patients while reducing the logistical burden on healthcare providers.

How does this launch strengthen Lupin’s diversification strategy amid U.S. pricing pressure?

Lupin Limited has been seeking to reposition its U.S. generics business through increased focus on specialty and complex products. The U.S. market, which once contributed significantly to Lupin Limited’s global revenue, has come under pressure in recent years due to pricing erosion and increased competition. In response, the company has invested in differentiated segments such as inhalation therapies, biosimilars, and injectables. The launch of Risperidone LAI with CGT exclusivity is viewed by analysts as a concrete outcome of these diversification efforts.

What are investors watching as Lupin ramps up Risperidone LAI commercialization in the U.S.?

Market observers believe that this launch will improve Lupin Limited’s near-term earnings visibility, particularly given the 180-day CGT exclusivity window. Institutional investors and brokerage firms are expected to closely track prescription volume ramp-up, formulary placements, and competitive response. The product’s success could also become a case study for future Lupin Limited launches under the PrecisionSphere platform, which may include candidates in hormonal, metabolic, and even oncology indications.

Can Lupin’s platform strategy become a commercial licensing model for other pharma players?

Analysts covering Lupin Limited anticipate that future filings using the same platform could receive regulatory tailwinds, especially if the first wave of CGT-exempt products demonstrates strong safety and market acceptance. There is also speculation that Lupin Limited could leverage this regulatory success to enter value-added licensing discussions with mid-sized pharmaceutical firms seeking lifecycle extension strategies for their mature brands. If such partnerships materialize, PrecisionSphere could evolve from an in-house innovation into a commercially licensed drug delivery platform similar to how other pharma majors have built platform-licensing businesses.

How does Lupin’s infrastructure and therapeutic footprint support future LAI expansion?

Lupin Limited’s broader business structure supports this ambition. The company operates 15 state-of-the-art manufacturing sites and seven research centers globally, backed by a workforce of over 24,000 professionals. It holds a strong market presence across therapy areas such as respiratory, cardiovascular, anti-infective, anti-diabetic, gastrointestinal, central nervous system, and women’s health. Through subsidiaries like Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions, the company is further embedding innovation in product delivery and patient engagement.

What could Lupin’s successful U.S. launch signal for Indian pharma’s innovation future?

The successful rollout of the Risperidone LAI under CGT exclusivity will likely serve as a bellwether for how Indian pharmaceutical companies can move beyond commoditized generics into more defensible and profitable categories. It also raises the bar for competitors in the Indian pharmaceutical space, many of whom are looking for the next growth frontier amid global price compression in plain-vanilla generics. For Lupin Limited, the stakes are clear, and the PrecisionSphere platform could be the fulcrum around which it pivots from traditional generic leader to innovation-driven pharmaceutical player.

As the U.S. market begins to adopt this formulation, all eyes will be on Lupin Limited’s ability to scale production, secure payor coverage, and maintain supply chain efficiency. The outcome will shape not just the commercial trajectory of Risperidone but also define the credibility of the company’s long-acting injectable ambitions going forward.

What are the most important takeaways investors and analysts should remember from Lupin’s PrecisionSphere-powered Risperidone launch in the U.S.?

• Lupin Limited has launched its first long‑acting injectable in the United States with 180‑day Competitive Generic Therapy exclusivity, giving it a temporary monopoly in a USD 187 million market.
• The product is bioequivalent to Risperdal Consta and enters critical psychiatric segments including schizophrenia and bipolar I disorder.
• This is the first commercial product built on Lupin Limited’s proprietary PrecisionSphere™ technology developed by Nanomi B.V., validating years of microsphere R&D investment.
• PrecisionSphere™ provides uniform microspheres, improved syringeability, and extended drug release from weeks to months, positioning Lupin Limited strongly in the complex generics segment.
• Executives highlighted that the launch demonstrates Lupin Limited’s technical capabilities and opens the door to global partnerships for long‑acting formulations.
• Analysts believe CGT exclusivity could significantly boost near‑term U.S. revenue and improve earnings visibility for Lupin Limited.
• The platform is expected to support a broader LAI pipeline across CNS, metabolic, hormonal, and potentially oncology therapies.
• Investor focus will now shift to production scale‑up, formulary coverage, prescription ramp‑up, and competitive entry once CGT exclusivity ends.
• Lupin Limited’s successful entry into the long‑acting injectable market may influence how Indian pharmaceutical firms pursue platform‑based innovation beyond commodity generics.